ATE334694T1 - Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln - Google Patents
Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmittelnInfo
- Publication number
- ATE334694T1 ATE334694T1 AT02800641T AT02800641T ATE334694T1 AT E334694 T1 ATE334694 T1 AT E334694T1 AT 02800641 T AT02800641 T AT 02800641T AT 02800641 T AT02800641 T AT 02800641T AT E334694 T1 ATE334694 T1 AT E334694T1
- Authority
- AT
- Austria
- Prior art keywords
- thymulin
- peptides
- producing pain
- pain relieves
- relieves
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- LIFNDDBLJFPEAN-BPSSIEEOSA-N (2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino Chemical class NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 LIFNDDBLJFPEAN-BPSSIEEOSA-N 0.000 abstract 1
- 108010087765 Antipain Proteins 0.000 abstract 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
- SDNYTAYICBFYFH-TUFLPTIASA-N antipain Chemical compound NC(N)=NCCC[C@@H](C=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 SDNYTAYICBFYFH-TUFLPTIASA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000011701 zinc Substances 0.000 abstract 1
- 229910052725 zinc Inorganic materials 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0112984A FR2830451B1 (fr) | 2001-10-09 | 2001-10-09 | Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE334694T1 true ATE334694T1 (de) | 2006-08-15 |
Family
ID=8868083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02800641T ATE334694T1 (de) | 2001-10-09 | 2002-10-08 | Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US7309690B2 (de) |
| EP (1) | EP1450843B1 (de) |
| JP (1) | JP4277684B2 (de) |
| AT (1) | ATE334694T1 (de) |
| AU (1) | AU2002362710B2 (de) |
| CA (1) | CA2463549C (de) |
| DE (1) | DE60213648T2 (de) |
| ES (1) | ES2272811T3 (de) |
| FR (1) | FR2830451B1 (de) |
| IL (2) | IL161319A0 (de) |
| WO (1) | WO2003030927A2 (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE477268T1 (de) | 2003-01-28 | 2010-08-15 | Ironwood Pharmaceuticals Inc | Zusammensetzungen zur behandlung von magen-darm- störungen |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CN102772783A (zh) * | 2007-01-25 | 2012-11-14 | 中国生化制药工业协会 | 血清胸腺因子在制备抗肿瘤药物、肿瘤物理及化学治疗药物的保护药物方面的用途 |
| MX2009013293A (es) | 2007-06-04 | 2010-02-15 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos. |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| FR2930156B1 (fr) | 2008-04-21 | 2011-10-28 | Cll Pharma | Utilisation du nonapeptide pat dans le traitement des maladies autoimmunes. |
| EP2810951B1 (de) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Für die Behandlung von gastrointestinalen Erkrankungen, Entzündungen, Krebs und anderen Erkrankungen geeignete Agonisten von Guanylatcyclase |
| CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| AU2009322285B2 (en) | 2008-12-03 | 2016-07-28 | Bausch Health Ireland Limited | Formulations of guanylate cyclase C agonists and methods of use |
| KR20170091783A (ko) | 2008-12-31 | 2017-08-09 | 알데릭스, 인코포레이티드 | 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법 |
| WO2018129556A1 (en) | 2017-01-09 | 2018-07-12 | Ardelyx, Inc. | Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US9468662B2 (en) | 2010-07-12 | 2016-10-18 | Orphit | Use of the PAT nonapeptide in the treatment and prevention of neurodegenerative diseases |
| FR2962335B1 (fr) * | 2010-07-12 | 2013-01-18 | Cll Pharma | Utilisation du nonapeptide pat dans le traitement et la prevention des maladies neurodegeneratives |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| CA3100941C (en) | 2011-03-01 | 2024-03-05 | Synergy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
| AU2013304812B2 (en) | 2012-08-21 | 2016-06-09 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| US10376481B2 (en) | 2012-08-21 | 2019-08-13 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| SMT201900386T1 (it) | 2013-04-12 | 2019-09-09 | Ardelyx Inc | Composti nhe3-leganti e metodi per l'inibizione del trasporto di fosfato |
| EA201592263A1 (ru) | 2013-06-05 | 2016-05-31 | Синерджи Фармасьютикалз, Инк. | Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования |
| AU2017276797A1 (en) * | 2016-06-06 | 2018-10-04 | Clinical Stem Cells Pty Ltd | Peptides for hair growth |
| AU2018205400C1 (en) | 2017-01-09 | 2026-01-15 | Ardelyx, Inc. | Compounds useful for treating gastrointestinal tract disorders |
| JP2020505333A (ja) | 2017-01-09 | 2020-02-20 | アルデリックス， インコーポレイテッド | Ｎｈｅ媒介性アンチポートの阻害薬 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH637111A5 (fr) * | 1977-05-25 | 1983-07-15 | Anvar | Composes polypeptidiques a activite thymique ou antagoniste et leurs procedes de synthese. |
| DK221681A (da) * | 1980-05-22 | 1981-11-23 | Inst Nat Sante | Fremgangsmaade til fremstilling af biologisk virksomme og radioimmunologisk anvendelige produkter ud fra serum-thymusfaktoren |
| JPS5852225A (ja) * | 1981-09-22 | 1983-03-28 | Mitsui Pharmaceut Inc | 脱髄疾患治療剤 |
| US5288706A (en) * | 1987-12-25 | 1994-02-22 | Mitsui Toatsu Chemicals, Incorporated | Medicament for prevention and remedy of diseases of the pancreas and others |
| JPH06192120A (ja) * | 1992-12-24 | 1994-07-12 | Mitsui Toatsu Chem Inc | 腎臓の組織・細胞の損傷・破壊の予防・治療剤 |
| JP3751986B2 (ja) * | 1994-06-21 | 2006-03-08 | 英良 横沢 | 医薬組成物 |
| US5639726A (en) * | 1994-09-30 | 1997-06-17 | The Regents Of The University Of Michigan | Peptide mediated enhancement of thrombolysis methods and compositions |
| US5808009A (en) * | 1996-09-23 | 1998-09-15 | North Dakota State University Research Foundation | Method of affinity purifying antibodies |
-
2001
- 2001-10-09 FR FR0112984A patent/FR2830451B1/fr not_active Expired - Fee Related
-
2002
- 2002-10-08 WO PCT/FR2002/003428 patent/WO2003030927A2/fr not_active Ceased
- 2002-10-08 CA CA2463549A patent/CA2463549C/fr not_active Expired - Fee Related
- 2002-10-08 US US10/492,170 patent/US7309690B2/en not_active Expired - Lifetime
- 2002-10-08 ES ES02800641T patent/ES2272811T3/es not_active Expired - Lifetime
- 2002-10-08 JP JP2003533958A patent/JP4277684B2/ja not_active Expired - Fee Related
- 2002-10-08 AT AT02800641T patent/ATE334694T1/de not_active IP Right Cessation
- 2002-10-08 AU AU2002362710A patent/AU2002362710B2/en not_active Ceased
- 2002-10-08 EP EP02800641A patent/EP1450843B1/de not_active Expired - Lifetime
- 2002-10-08 DE DE60213648T patent/DE60213648T2/de not_active Expired - Lifetime
- 2002-10-08 IL IL16131902A patent/IL161319A0/xx active IP Right Grant
-
2004
- 2004-04-07 IL IL161319A patent/IL161319A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2830451B1 (fr) | 2004-04-30 |
| JP2005515972A (ja) | 2005-06-02 |
| DE60213648T2 (de) | 2007-08-02 |
| WO2003030927A3 (fr) | 2003-10-09 |
| WO2003030927A2 (fr) | 2003-04-17 |
| US20050261194A1 (en) | 2005-11-24 |
| CA2463549C (fr) | 2011-12-20 |
| US7309690B2 (en) | 2007-12-18 |
| ES2272811T3 (es) | 2007-05-01 |
| EP1450843B1 (de) | 2006-08-02 |
| JP4277684B2 (ja) | 2009-06-10 |
| FR2830451A1 (fr) | 2003-04-11 |
| AU2002362710B2 (en) | 2007-06-28 |
| IL161319A0 (en) | 2004-09-27 |
| DE60213648D1 (de) | 2006-09-14 |
| AU2002362710B8 (en) | 2003-04-22 |
| CA2463549A1 (fr) | 2003-04-17 |
| EP1450843A2 (de) | 2004-09-01 |
| IL161319A (en) | 2008-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60213648D1 (de) | Verwendung von thymulinähnlichen peptiden zur herstellung von schmerzmitteln | |
| DE60225118D1 (de) | Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden | |
| IL161591A0 (en) | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells | |
| TW200602071A (en) | Methods for preventing and treating alzheimer's disease (ad) | |
| ATE429922T1 (de) | Topische gel-abgabesysteme zur behandlung von hauterkrankungen | |
| DE69738581D1 (de) | Menschliche dnase i hyperaktive varianten | |
| ATE232393T1 (de) | Verwendung von substanzen mit oxytocinwirkung zur herstellung von arzneimitteln zur wundheilung | |
| NL300830I1 (nl) | Protein Q, een recombinant chimeer eiwit, bestaande uit vijf antigenefragmenten van vier verschillende Leishmania infantum (zymodeme Mon-1) eiwitten | |
| GB2367061A (en) | Peptides | |
| YU68702A (sh) | Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka | |
| HUP9900789A2 (hu) | Lefelé irányuló szabályozásra rezisztens C3 konvertáz | |
| ATE356145T1 (de) | Polypeptide zur regenerierung des nervensystems | |
| DE59410423D1 (de) | Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose | |
| DE69738600D1 (de) | Neuroaktive peptide | |
| FI20050753A0 (fi) | Uudet peptidit | |
| ATE239492T1 (de) | Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen | |
| NO20004393L (no) | Anvendelse av CD137 for Õ fremme proliferering av perifere monocytter | |
| DE59805246D1 (de) | Tissue-faktor zur beeinflussung von gefässbildung | |
| ATE218866T1 (de) | Kombinationstherapie zur behandlung von aids | |
| DE69813620D1 (de) | Verwendung von citrullin enthaltenden peptiden, die von filaggrin abstammen, zur behandlung von autoimmunkrankheiten | |
| DE602006017806D1 (de) | Behandlung von neurodegeneration | |
| SE9703287D0 (sv) | Peptides | |
| ATE446766T1 (de) | Verwendung von alpha-s2 casein vorläufer- abgeleiteten peptiden | |
| ATE374021T1 (de) | Verwendung von l-azetylcarnitin zur herstellung eines medikaments zur präventiven post- chirurgischen schmerzbehandlung | |
| ATE226443T1 (de) | Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |